MM_Hub: CONGRESS|#EHA2021|@szusmani @LevineCancer presented poster for results from CARTITUDE-1 study where a single infusion of cita-cel yielded deep & durable responses in heavily pretreated MM pts with manageable safety profile at RP2D #mmsm #myeloma

by | Jun 16, 2021 | Twitter

CONGRESS|#EHA2021|@szusmani @LevineCancerpresented poster for results from CARTITUDE-1 study where a single infusion of cita-cel yielded deep & durable responses in heavily pretreated MM pts with manageable safety profile at RP2D #mmsm #myeloma...

MM_Hub: CONGRESS|#EHA2021| Juan-José Garcés @idisnanavarra presented that circulating tumor cells (CTC) were the most relevant prognostic factor at baseline in MM pts. Undetectable MRD should be the treatment endpoint for CTC elevated pts as they showed long-term survival #mmsm #myeloma

by | Jun 15, 2021 | Twitter

CONGRESS|#EHA2021| Juan-José Garcés @idisnanavarra presented that circulating tumor cells (CTC) were the most relevant prognostic factor at baseline in MM pts. Undetectable MRD should be the treatment endpoint for CTC elevated pts as they showed long-term survival...

MM_Hub: CONGRESS|#EHA2021| Jason Valent, Taussig Cancer Institute presented study on safety & tolerability through 4 weeks of treatment with CAEL-101+CyBorD & CAEL-101+CyBorD+daratumumab in amyloidosis pts. 1000mg/sq.m was well-tolerated. #mmsm,#myeloma

by | Jun 15, 2021 | Twitter

CONGRESS|#EHA2021| Jason Valent, Taussig Cancer Institute presented study on safety & tolerability through 4 weeks of treatment with CAEL-101+CyBorD & CAEL-101+CyBorD+daratumumab in amyloidosis pts. 1000mg/sq.m was well-tolerated. #mmsm,#myeloma...

MM_Hub: CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma

by | Jun 14, 2021 | Twitter

CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma...